World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
QNTMTORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), understands that Quantum BioPharma shareholder Paul Durkacz has filed a class action lawsuit alleging that investors in Quantum BioPharma were the victims of stock manipulation. The suit alleges that between January 6, 2021, and October 15, 2025, shareholders who sold securities of Quantum Biopharma Ltd., formerly known as FSD Pharma Inc., were significantly and materially harmed.
Quantum BioPharma Announces Corporate Updates
QNTMTORONTO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the following corporate updates:
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
QNTMTORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., that it has signed an agreement with a leading contract development and manufacturing organization (CDMO) to manufacture an oral drug formulation of Lucid-MS. The oral formulation of Lucid-MS will serve as the drug product for the Company’s Phase 2 clinical trial, which will test the efficacy on humans of Lucid-MS as a possible treatment for people to gain back mobility lost with multiple sclerosis (MS). To date numerous animal models over the past decade showed Lucid-MS helped those animals regain their ability to walk. Videos can be seen at https://www.quantumbiopharma.com/lucid-ms.
Quantum Biopharma Purchases Additional Bitcoin, Bringing Total Amount OF Crypto Purchased To $5M
QNTMWhat's Going On With Quantum Biopharma Stock Today?
QNTMQuantum Biopharma surges 15% after $2.35M settlement ends legal battle with ex-CEO Raza Bokhari.
Quantum Biopharma Licensee Celly Nutrition Changes Name To Unbuzzd Wellness Inc. Effective May 23, 2025
QNTMQuantum BioPharma Subsidiary, FSD Pharma Australia Pty, Received Human Ethics Review Committee Approval For Trial Entitled A Randomized, Double-Blind Placebo Controlled Parallel Group Decentralized Trial to Assess the Safety and Efficacy of FSD202 in Part
QNTMQuantum BioPharma Joins Forces with MGH To Conduct Clinical Study On Innovative PET Imaging For Multiple Sclerosis
QNTMQuantum Biopharma Announced Its Licensee Celly Nutrition Corporatio Released New Unbuzzd On-the-go Powder Stick Packs In An 8-pack Display Box, Facilitating The Sale Of Unbuzzd In Convenience, Liquor, And Drug Stores Across The United States
QNTMQuantum Biopharma's Lucid-21-302 Passes Phase 1 Safety Review, Advancing Toward Phase 2 In MS Treatment
QNTMQuantum BioPharma Says It Diversified Treasury With The Purchase Of Usd $1M Of Bitcoin And Other Cryptocurrencies And To Allow For Future Financings And Other Transactions In Cryptocurrency
QNTM